<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
        <journal-id journal-id-type="iso-abbrev">J. Clin. Oncol</journal-id>
        <journal-id journal-id-type="pmc-domain-id">660</journal-id>
        <journal-id journal-id-type="pmc-domain">jco</journal-id>
        <journal-id journal-id-type="publisher-id">JCO</journal-id>
        <journal-title-group>
          <journal-title>Journal of Clinical Oncology</journal-title>
        </journal-title-group>
        <issn pub-type="ppub">0732-183X</issn>
        <issn pub-type="epub">1527-7755</issn>
        <publisher>
          <publisher-name>American Society of Clinical Oncology</publisher-name>
        </publisher>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC5477828</article-id>
        <article-id pub-id-type="pmcid-ver">PMC5477828.1</article-id>
        <article-id pub-id-type="pmcaid">5477828</article-id>
        <article-id pub-id-type="pmcaiid">5477828</article-id>
        <article-id pub-id-type="pmid">27646943</article-id>
        <article-id pub-id-type="doi">10.1200/JCO.2016.68.7798</article-id>
        <article-id pub-id-type="publisher-id">687798</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="subjects">
            <subject>Chemotherapy</subject>
            <subject>Translational Oncology</subject>
          </subj-group>
          <subj-group subj-group-type="heading">
            <subject>ORIGINAL REPORTS</subject>
            <subj-group>
              <subject>Translational Oncology</subject>
            </subj-group>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors</article-title>
          <alt-title alt-title-type="short">Genetic Determinants of Cisplatin Resistance in Advanced GCT</alt-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bagrodia</surname>
              <given-names initials="A">Aditya</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="BH">Byron H.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lee</surname>
              <given-names initials="W">William</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cha</surname>
              <given-names initials="EK">Eugene K.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sfakianos</surname>
              <given-names initials="JP">John P.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Iyer</surname>
              <given-names initials="G">Gopa</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Pietzak</surname>
              <given-names initials="EJ">Eugene J.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Gao</surname>
              <given-names initials="SP">Sizhi Paul</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zabor</surname>
              <given-names initials="EC">Emily C.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Ostrovnaya</surname>
              <given-names initials="I">Irina</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kaffenberger</surname>
              <given-names initials="SD">Samuel D.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Syed</surname>
              <given-names initials="A">Aijazuddin</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Arcila</surname>
              <given-names initials="ME">Maria E.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chaganti</surname>
              <given-names initials="RS">Raju S.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Kundra</surname>
              <given-names initials="R">Ritika</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Eng</surname>
              <given-names initials="J">Jana</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hreiki</surname>
              <given-names initials="J">Joseph</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Vacic</surname>
              <given-names initials="V">Vladimir</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Arora</surname>
              <given-names initials="K">Kanika</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Oschwald</surname>
              <given-names initials="DM">Dayna M.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bajorin</surname>
              <given-names initials="DF">Dean F.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bains</surname>
              <given-names initials="MS">Manjit S.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Schultz</surname>
              <given-names initials="N">Nikolaus</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reuter</surname>
              <given-names initials="VE">Victor E.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Sheinfeld</surname>
              <given-names initials="J">Joel</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Bosl</surname>
              <given-names initials="GJ">George J.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Al-Ahmadie</surname>
              <given-names initials="HA">Hikmat A.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
          </contrib>
          <contrib contrib-type="author" corresp="yes">
            <name name-style="western">
              <surname>Feldman</surname>
              <given-names initials="DR">Darren R.</given-names>
            </name>
            <xref ref-type="aff" rid="aff1"/>
            <xref ref-type="corresp" rid="cor1"/>
          </contrib>
          <aff id="aff1">Aditya Bagrodia, Byron H. Lee, William Lee, Eugene K. Cha, Gopa Iyer, Eugene J. Pietzak, Sizhi Paul Gao, Emily C. Zabor, Irina Ostrovnaya, Samuel D. Kaffenberger, Aijazuddin Syed, Maria E. Arcila, Raju S. Chaganti, Ritika Kundra, Jana Eng, Joseph Hreiki, Michael F. Berger, Dean F. Bajorin, Manjit S. Bains, Nikolaus Schultz, Victor E. Reuter, Joel Sheinfeld, George J. Bosl, Hikmat A. Al-Ahmadie, David B. Solit, Darren R. Feldman, Memorial Sloan Kettering Cancer Center; John P. Sfakianos, Icahn School of Medicine at Mount Sinai; Gopa Iyer, Michael F. Berger, Dean F. Bajorin, Manjit S. Bains, Victor E. Reuter, Joel Sheinfeld, George J. Bosl, Hikmat A. Al-Ahmadie, David B. Solit, Darren R. Feldman, Weill Cornell Medical College; and Vladimir Vacic, Kanika Arora, Dayna M. Oschwald, New York Genome Center, New York, NY.</aff>
        </contrib-group>
        <author-notes>
          <fn id="afn1" fn-type="equal">
            <p>A.B. and B.H.L. contributed equally to this work.</p>
          </fn>
          <corresp id="cor1">Corresponding author: Darren R. Feldman, MD, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065; e-mail: <email>feldmand@mskcc.org</email>.</corresp>
          <fn id="fn3" fn-type="COI-statement">
            <p>Authors’ disclosures of potential conflicts of interest are found in the article online at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.jco.org">www.jco.org</ext-link>. Author contributions are found at the end of this article.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="ppub">
          <day>20</day>
          <month>11</month>
          <year>2016</year>
        </pub-date>
        <pub-date pub-type="epub">
          <day>19</day>
          <month>9</month>
          <year>2016</year>
        </pub-date>
        <volume>34</volume>
        <issue>33</issue>
        <issue-id pub-id-type="pmc-issue-id">294190</issue-id>
        <fpage>4000</fpage>
        <lpage>4007</lpage>
        <pub-history>
          <event event-type="pmc-release">
            <date>
              <day>20</day>
              <month>05</month>
              <year>2017</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>29</day>
              <month>06</month>
              <year>2017</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2020-02-07 22:56:18.150">
              <day>07</day>
              <month>02</month>
              <year>2020</year>
            </date>
          </event>
        </pub-history>
        <permissions>
          <copyright-statement>© 2016 by American Society of Clinical Oncology</copyright-statement>
          <copyright-year>2016</copyright-year>
          <copyright-holder>American Society of Clinical Oncology</copyright-holder>
        </permissions>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="JCO.2016.68.7798.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:title="pdf" xlink:href="JCO.2016.68.7798.pdf"/>
        <abstract>
          <sec>
            <title>Purpose</title>
            <p>Owing to its exquisite chemotherapy sensitivity, most patients with metastatic germ cell tumors (GCTs) are cured with cisplatin-based chemotherapy. However, up to 30% of patients with advanced GCT exhibit cisplatin resistance, which requires intensive salvage treatment, and have a 50% risk of cancer-related death. To identify a genetic basis for cisplatin resistance, we performed whole-exome and targeted sequencing of cisplatin-sensitive and cisplatin-resistant GCTs.</p>
          </sec>
          <sec>
            <title>Methods</title>
            <p>Men with GCT who received a cisplatin-containing chemotherapy regimen and had available tumor tissue were eligible to participate in this study. Whole-exome sequencing or targeted exon-capture–based sequencing was performed on 180 tumors. Patients were categorized as cisplatin sensitive or cisplatin resistant by using a combination of postchemotherapy parameters, including serum tumor marker levels, radiology, and pathology at surgical resection of residual disease.</p>
          </sec>
          <sec>
            <title>Results</title>
            <p><italic toggle="yes">TP53</italic> alterations were present exclusively in cisplatin-resistant tumors and were particularly prevalent among primary mediastinal nonseminomas (72%). <italic toggle="yes">TP53</italic> pathway alterations including <italic toggle="yes">MDM2</italic> amplifications were more common among patients with adverse clinical features, categorized as poor risk according to the International Germ Cell Cancer Collaborative Group (IGCCCG) model. Despite this association, <italic toggle="yes">TP53</italic> and <italic toggle="yes">MDM2</italic> alterations predicted adverse prognosis independent of the IGCCCG model. Actionable alterations, including novel <italic toggle="yes">RAC1</italic> mutations, were detected in 55% of cisplatin-resistant GCTs.</p>
          </sec>
          <sec>
            <title>Conclusion</title>
            <p>In GCT, <italic toggle="yes">TP53</italic> and <italic toggle="yes">MDM2</italic> alterations were associated with cisplatin resistance and inferior outcomes, independent of the IGCCCG model. The finding of frequent <italic toggle="yes">TP53</italic> alterations among mediastinal primary nonseminomas may explain the more frequent chemoresistance observed with this tumor subtype. A substantial portion of cisplatin-resistant GCTs harbor actionable alterations, which might respond to targeted therapies. Genomic profiling of patients with advanced GCT could improve current risk stratification and identify novel therapeutic approaches for patients with cisplatin-resistant disease.</p>
          </sec>
        </abstract>
        <counts>
          <fig-count count="4"/>
          <table-count count="3"/>
          <equation-count count="0"/>
          <ref-count count="20"/>
          <page-count count="12"/>
        </counts>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name> DJS Export </meta-name>
            <meta-value>v1</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
